Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

NIH NIAID ACTT-1
  NCT04280705		 RCTremdesivirplaceboCOVID 19 hospitalizedsome concern
541/521 suggested
  • suggested 45 % decrease in deaths,deaths (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 29 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 35 % increase in clinical improvement (28-day) with a moderate degree of certainty due to some concern in risk of bias

COVID-19 severe or critically meta-analysis

CAP-China (Wang et al.)
  NCT04257656		 RCTremdesivirplaceboCOVID-19 severe or criticallylow
158/79 inconclusive
  • inconclusive 23 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a high degree of certainty due to low risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons